Zobrazeno 1 - 10
of 28
pro vyhledávání: '"S.D. Rencher"'
Autor:
Julia L. Hurwitz, S.D. Rencher
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 16:69-73
In past years, much attention has been paid to the HIV-1 envelope (env) protein variable region 3 (V3), termed the principal neutralizing determinant. HIV-1 vaccines were often designed to target V3, and vaccine efficacy was often measured with V3-ba
Publikováno v:
Virology. 196:179-189
The mechanism by which Epstein-Barr Virus (EBV) escapes T-cell activity during latency in immunocompetent individuals has long been debated. In order to identify potential weaknesses in the EBV-specific immune response, a study of T-cell receptors (T
Publikováno v:
Human Immunology. 37:178-184
TCR V alpha 3 and V alpha 5 transcripts in PBLs from healthy individuals of multiple age groups and from BMT recipients were analyzed. PCR, cloning, and sequencing studies revealed significant V-J junctional diversity among TCR transcripts from all t
Publikováno v:
AIDS Research and Human Retroviruses. 12:1297-1299
Autor:
Pamela Freiden, R V Srinivas, Nanna Howlett, Peter C. Doherty, S.D. Rencher, Timothy D. Lockey, Karen S. Slobod, Julia L. Hurwitz
Publikováno v:
European journal of clinical microbiologyinfectious diseases : official publication of the European Society of Clinical Microbiology. 23(2)
A critical goal of HIV vaccine development is the identification of safe and immunogenic vectors. Recombinant vaccinia virus is a highly effective vaccine vector, with demonstrated capacity to protect animals from various viral pathogens, including r
Publikováno v:
AIDS Research and Human Retroviruses. 11:1131-1133
Publikováno v:
Vaccine. 15(3)
Recombinant vaccinia virus (VV) vectors that express the envelope (Env) protein of the human immunodeficiency virus-type 1 (HIV-1) have been previously shown to elicit HIV-specific cytotoxic T-lymphocyte (CTL) and weak antibody responses in non-human
Publikováno v:
Cancer immunology, immunotherapy : CII. 41(2)
Allogeneic bone marrow transplantation (BMT) has become a therapy of choice for the treatment of certain malignancies and hematopoietic disorders. However, immunodeficiencies following BMT continue to cause significant morbidity and mortality. We hav
Publikováno v:
Transplantation. 58(5)
Publikováno v:
AIDS research and human retroviruses. 10(7)